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Abstract
Gastrointestinal stromal tumor (GIST) is a rare but an important clinical entity
seen in our clinical practice. It is the most common mesenchymal tumor of the
gastrointestinal tract and most common malignancy of the small intestine.
Although the exact prevalence of GIST is not known, the incidence of GIST has
been increasing. GISTs arise from interstitial cells of Cajal. Most of the GISTs
occur due to mutation in c-kit gene or platelet derived growth factor receptor
alpha gene. 15% of GISTs do not have these mutations and they are called wildtype GISTs. Almost all GISTs express KIT receptor tyrosine kinase. Histologically,
GISTs look like spindle cell tumors most of the time but they can be epitheloid or
mixed type. The median size of GISTs varies from 2.7 cm to 8.9 cm. Clinically,
patients with small GISTs remain asymptomatic but as the GIST size increases,
patients present with various symptoms depending on the location of the GIST.
Most of GISTs are located in the stomach or small bowel. Diagnosis is suspected
on imaging and endoscopic studies, and confirmed by tissue acquisition with
immunohistochemical staining. The aggressiveness of GISTs depends on the size,
mitotic index and location. Surgical resection is the treatment of choice. But
various endoscopic modalities of resection are increasingly being tried. Tyrosine
kinase inhibitors are extremely useful in the management of large GISTs,
unresectable GISTs and metastatic GISTs. Treatment options for metastatic GISTs
also include radiotherapy, chemotherapy, hepatic artery embolization,
chemoembolization and radiofrequency ablation.
Key words: Gastrointestinal stromal tumor; Mesenchymal tumor of gastrointestinal tract;
Gastrointestinal subepithelial tumors; Management of gastrointestinal stromal tumor;
Familial gastrointestinal stromal tumor; Risk stratification
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Core tip: Gastrointestinal stromal tumors are increasingly being diagnosed in our clinical
practice with the availability of various imaging, endoscopic and endosonographic studies.
Now we have better understanding of the pathophysiology of this tumor. A new tyrosine
kinase inhibitor is now approved for the treatment of this tumor refractory to other agents
in the same class. There is an increased interest in endoscopic resection of this tumor.
Updated recommendation for the management of gastrointestinal stromal tumors will also
be discussed in this review.
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INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are rare gastrointestinal (GI) neoplasms
accounting for 0.1 to 3% of all GI malignancies[1]. But they are the most common (80%)
mesenchymal tumors of the GI tract[2]. They arise from the spindle shaped
mesenchymal cells called interstitial cells of Cajal (ICCs) or stem cell precursors to
these cells. ICCs are the GI pacemaker cells (specialized nerve cells) present in the
muscularis propria and around the myenteric plexus. Most (50%-70%) of the GISTs are
located in the stomach (70% in gastric body, 15% in antrum and 15% in cardia) or
small intestine (30% in jejunum or ileum, 5% in duodenum) but they can arise in any
part of the GI tract (colon, rectum, appendix together – 5% and esophagus 2%-3%), and
rarely in the extra-GI site (mesentery, omentum, retroperitoneum and pancreas) where
they arise from stem cell precursors to ICC[3]. The incidence of GISTs has been
increasing over the last few decades. They generally occur in the middle aged and
older population (median age 60-65 years) with slight male predominance (3:1)[4].
Patients may remain asymptomatic for long period of time until complication or
metastasis occurs. Most of the time, GISTs are diagnosed incidentally in imaging
studies, endoscopic evaluations, during surgical procedures or autopsy. Instead of
classifying as benign or malignant, they are stratified as low risk and high risk GISTs
depending on mitotic index, tumor size and tumor locations. They can have slow
growing indolent course or fast growing, metastasizing and life threatening course.
The prognosis can be excellent if they can be diagnosed and treated early. In the past,
GISTs were thought to be originating from smooth muscles as they have smooth
muscle features on light microscopy. In 1980s, they were named as stromal tumors as
they were found to have no immunophenotypic features of smooth muscles on
immunohistochemistry. In 1998, Kindblom and associates first reported that GISTs
originated from ICCs[5]. In this article, the epidemiology, pathophysiology, histology,
clinical aspects, diagnosis, the updated treatment strategy and prognosis of GISTs will
be reviewed.

EPIDEMIOLOGY
In the United States (US), about 5000–6000 new cases of GISTs are diagnosed per
year[6]. As per Surveillance, Epidemiology, and End Results database, the incidence of
GIST increased from 0.55/100000 population in 2001 to 0.78/100000 population in
2011[7]. Another study published in 2006 showed that there was 25-fold increase in
incidence of GISTs in the US in 10 years since 1992[8]. In Europe, the incidence of GIST
varies from 6.5 to 14.5 per million per year[9-11]. The exact of prevalence of GIST is not
known. But it assumed that as many cases remain silent throughout their life, the
prevalence of GISTs is possibly high. One German study on consecutive autopsies
found the presence of subcentimeter GISTs in 22.5% of individuals older than 50
years[12]. The real incidence of GIST is not known because a lot of tumors have not been
tested for the KIT or the Platelet derived growth factor receptor alpha (PDGFRA) gene
mutations.
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PATHOPHYSIOLOGY
Uncontrolled proliferation of ICCs leads to the development of GISTs. The c-kit protooncogene located on chromosome 4q 11-12 encodes the transmembrane tyrosine
kinase KIT[13]. The great discovery of gain-of-function mutation of c-KIT in human
GISTs was published by Hirota et al[14] in 1998. Exon 11 (transmembrane domain) is
involved in 90% of KIT gene mutation[15]. KIT-activating mutations lead to ICCs
hyperplasia and GISTs. KIT gene mutation with constitutive activation of tyrosine
kinase is found in 75% of GISTs. PDGFRA gene at chromosome 4q12 controls
production of PDGFRA which is a part of a family of proteins called receptor tyrosine
kinase (RTKs). The most common PDGFRA mutation is Asp842Val substitution in
exon18. Intragenic activation mutation of PDGFRA gene with production of RTKs was
found in about 35% of GISTs lacking KIT gene mutations[16]. Thus the growth of GISTs
is propelled by mutation of either KIT gene (75% of cases) or PDGFRA gene (10% of
cases). The oncogenic mechanisms appear to be alternative and mutually exclusive.
GISTs associated with either KIT or PDGFRA gene mutations are indistinguishable
with respect to cytogenetic changes associated with tumor progression. But GISTs
associated with PDGFRA mutation due to Asp842Val substitution in exon18 is
resistant to tyrosine kinase inhibitor (TKI) imatinib mesylate. About 15% of GISTs do
not have detectable KIT or PDGFRA gene mutation. These are so-called ‘wild-type’
GISTs or pediatric GISTs. Wild-type GISTs should be tested for germ-line mutation in
the SDH gene (SDH deficient by immunohistochemistry). Clinically, they cannot be
distinguished from KIT or PDGFRA-mutant GISTs and have the same morphology,
express high levels of KIT, and occur in any part of the GI tract[17]. Few other genetic
mutations have been detected in wild-type GISTs. These include BRAF, HRAS, NRAS,
PIK3CA gene mutations. Germline mutation of KIT or PDGFRA occurs in familial GIST
which is extremely rare (< 0.1%) and autosomal dominant. Patients generally present
in middle age of life with multiple GISTs. Familial GISTs have benign course and do
not decrease life span[18]. GISTs can also be associated with certain syndromes. These
include: (1) Neurofibromatosis type 1- multifocal small GISTs with low risk feature
occur in small intestine. GISTs do not have KIT or PDGFRA mutation; (2) CarneyStratakis syndrome – SDH-deficient GIST and paraganglioma due to germline
mutation of SDHA, SDHB, or SDHC [19]; and (3) Carney triad –gastric GISTs,
paraganglioma and pulmonary chondromas. GISTs are multifocal with high local
recurrence rate. The above syndromes lack KIT or PDGFRA gene mutation.
Immunohistochemistry is important to identify GISTs from other spindle cell or
epitheloid tumors. GISTs are generally negative for desmin (smooth muscle marker)
and S100 protein (Schwann cell marker) but can be variably positive for smooth
muscle actin and muscle-specific actin[20]. 70% of GISTs stain positive for CD34 which
was the first immunohistochemical marker identified in1984 to differentiate GIST from
leiomyoma and leiomyosarcoma. CD117 (KIT) is a sensitive and more specific marker
for GIST discovered in 1998[21]. DOG1 (a calcium-dependent chloride channel protein
anoctamin) is a novel marker ubiquitously expressed in GISTs irrespective of KIT or
PDGFRA mutation status[22]. It was first discovered in 2004. CD117 and DOG1 each
stain positive in more than 95% of GISTs. KIT receptor tyrosine kinase is expressed by
almost all GISTs[23]. It is not sufficient to establish the diagnosis of GIST just on the
basis of immunohistochemical staining (IHS). Some extra-intestinal malignancies
which can stain positive for KIT include small cell lung cancer, metastatic melanoma,
angiosarcoma and Ewing’s sarcoma[24].

HISTOLOGY
GISTs are well-circumscribed tumors ranging in size from < 1 cm to > 40 cm in
diameter, the median size varies from 2.7 cm (when diagnosed incidentally) to 8.9 cm
(when a patient is symptomatic)[10,25]. Histologically, they are of 3 types: spindle cell
type (70%), epitheloid type (20%) and mixed type (10%). Spindle cell types have
compact and highly cellular spindle shaped cells which have fibrillary eosinophilic
cytoplasm, ovoid nuclei with frequent paranuclear vacuolization, syncytial cell
borders and are arranged in a storiform, fascicular pattern with minimal stroma.
Dense deposits of collagen are also seen in the extracellular space. In epitheloid type,
the cells have abundant pale eosinophilic to clear cytoplasms, round nuclei, distinct
cellular borders and are arranged in sheets, nests or cords. Mixed types have
combination of spindle cells and epitheloid cells. Rarely, GISTs contain acellular PAS
stain positive collagen bundles known as skenoid fibers. Irrespective of the type, a
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variable inflammatory infiltrate (lymphocytes and plasma cells), hemorrhage, necrosis
and sclerosis can be present. Degeneration and necrosis can be seen in GIST histology.
There can be complete absence or high mitotic activity[26,27]. Mitotic index calculated by
counting the number of mitoses per 50 high-power fields is an important indicator of
proliferative activity and prognosis of GIST.

Extragastrointestinal stromal tumors
Less than 5% of all GISTs are located outside the GI tract[28]. Most of the
extragastrointestinal stromal tumors (EGISTs) are found in the mesentery or omentum
but other sites of involvement include retroperitoneum, pancreas, spleen, falciform
ligament, hepatogastric ligament, mediastinum and pelvis[29]. EGISTs are generally
discovered during imaging studies and surgery. Tissue diagnosis is made by
computerized tomography (CT)-guided or ultrasound-guided biopsy with IHS. They
carry an aggressive course and poor prognosis if the GIST size is > 5 cm with mitotic
rate of > 5/50 HPF.

Composite tumors with a GIST component
Coexistence of two different tumors i.e. collision tumors are extremely rare and
generally detected in the surgically resected specimen. Collision tumors with
coexistence of adenocarcinoma and GIST in the stomach and small intestine have been
reported[30].

CLINICAL ASPECTS
As mentioned before, GISTs are now-a-days detected more and more by various
imaging studies like CT, magnetic resonance imaging (MRI) and endoscopic
ultrasound (EUS). Small GISTs do not produce any symptom or sign. But when they
become larger in size, patients generally present with GI bleeding due to mucosal
ulceration, abdominal pain or obstruction due to mass effect. In about 50% of cases,
mucosal ulceration is seen on the luminal surface of the GIST[31]. Of course, symptoms
and signs depend on the location of the tumor. Gastric GISTs may present with
hematemesis, melena, dyspepsia, nausea, vomiting or early satiety. Duodenal GISTs
are well-defined round or oval subepithelial masses, generally located in the second
through the fourth part of duodenum. They do not cause duodenal obstruction or
lymphadenopathy but they may cause bleeding, ampullary obstruction and jaundice.
They may also metastasize frequently to the liver and peritoneum[32]. About 10% of
gastric GISTs and 15% of duodenal GISTs may present emergently with upper GI
bleeding. Small intestinal (jejunal – 40%, ileal - 60%) GISTs may present with small
bowel bleeding, fatigue (due to anemia), abdominal pain and intestinal obstruction.
They cause acute abdominal symptoms more frequently than duodenal GISTs[33].
Esophageal GISTs may present with dysphagia. Mesenteric or omental GISTs may
present as abdominal masses. 8% of GISTs may present with acute abdominal
emergency due to bowel wall rupture and peritonitis[34]. Occasionaally tumor rupture
into the peritoneal cavity may also cause intraabdominal bleeding and peritoneal
seeding of tumor cells[35]. GISTs generally metastasize to the liver and intra-abdominal
cavity but rarely they metastasize to the lungs and bones. Anorectal GISTs are welldefined subepithelial tumors with an average size of 6.9 cm. They represent 5% of all
GISTS. Most of the anorectal GISTs are asymptomatic, and are detected during
endoscopic or imaging studies. Symptomatic patients may present with proctalgia
(34%) or recal bleeding (25%)[36].

DIAGNOSIS
There is no supportive or confirmatory Laboratory test for GISTs. Imaging studies or
endoscopic evaluations are done according to patient’s clinical presentation. As most
of the GISTs occur in the stomach or small bowel, contrast-enhanced CT may show an
intramural endophytic or exophytic (as GISTs generally involve the outer longitudinal
muscular layer) hypervascular mass in the gastric or small bowel wall. Small (< 5 cm)
GISTs are homogenous, smooth-walled and sharply margined masses whereas large
(> 5 cm) GISTs are heterogenous (due to hemorrhage, necrosis or cystic degeneration)
masses with well-defined or ill-defined margins and rare calcifications. CT is the most
commonly used modality in the diagnosis of primary and metastatic GISTs. It is
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helpful not only in the initial diagnosis but also in following the natural progression of
GISTs and the response of GISTs to treatment[37]. On CT, GISTs are mainly iso to
minimally hypodense to the muscle layer. In response to effective treatment, GISTs
decreases in size and becomes more homogenous with disappearance of nodules. On
the other hand, appearance of nodule in the GIST following treatment indicates
recurrence of the disease. The main drawback of CT is inability to differentiate
between inflammatory adhesions and involvement of contiguous organs. In case of
gastric GISTs it is difficult to decide if the tumor arises from the stomach, pancreas,
liver or colon. MRI is adjunctive to CT in the evaluation of GISTs. On MRI, small GISTs
are generally round and homogenous with strong arterial enhancement while large
GISTs are usually lobulated and mildly heterogenous with gradual enhancement due
to hemorrhage, necrosis and cystic changes[38]. MRI is more useful in the evaluation of
anorectal GISTs and metastatic hepatic GISTs. On MRI, GISTs are iso to minimally
hypointense to the muscle layer on T1-weighted images and hyperintense on T2weighted images. More than 90% of GISTs are fluorodeoxyglucose (FDG) avid with a
mean baseline standard uptake value of 5.8 on FDG-positron emission tomography
(FDG-PET)[39]. A baseline FDG-PET should be done prior to initiation of therapy. It is
an ideal test not only for staging of GISTs but also for assessing therapeutic response,
evaluating primary and secondary resistance to treatment, and resolving discrepant
findings between clinical status and CT results. Primary resistance to TKI therapy can
be identified by seeing lack of metabolic response on FDG-PET shortly after initiation
of therapy. Secondary resistance to TKI will show re-emergence of metabolic activity
(hot spot) on a quiescent area within the GIST following a period of therapeutic
response. Combined hybrid PET/CT scanning can be the optimal test for the
evaluation of patients treated with TKI[40]. Endoscopically, GISTs appear as spherical or
hemispherical smooth, subepithelial polypoid lesions which are further evaluated by
EUS. Most commonly GISTs originate from the muscularis propria i.e., echo-poor 4th
EUS layer of the GI wall but rarely they can originate from the echo-poor 2nd layer i.e.,
muscularis mucosae[41]. Endosonographically, they appear as inhomogeneous,
hypoechoic lesions, their differential diagnoses include leiomyoma, lymphoma and
schwannoma[42]. Tissue diagnosis should be done by EUS guided fine needle aspiration
(FNA) for > 1 cm lesion or true cut biopsy (TCB) for 2 to 5 cm lesion, particularly if
non-GIST histology like leiomyoma is suspected[43]. EUS-guided FNA/TCB should also
be considered if it is a very large GIST needing neoadjuvant therapy with TKI. Tissue
acquisition may not be necessary if it is a very large, symptomatic GIST with
malignant features on EUS and has to be resected by surgery irrespective of FNA/TCB
result. High risk malignant features on EUS include large size of the GIST (≥ 2 cm),
irregular borders, presence of heterogenous echogenicity, anechoic (cystic) spaces,
ulceration, echogenic foci, a marginal halo and increase in size during follow up[44,45].
Endoscopically, focal mucosal ulceration of the GIST is common and is not related to
malignancy[46]. Endoscopic, endosonographic or imaging features are suggestive but
not diagnostic of GIST. Histopatholgy with hematoxylin and eosin staining alone is
not sufficient to establish the diagnosis of GIST. Definitive diagnosis of GIST is
established when there is concordance between histology and IHS with KIT, CD34 or
DOG1.

RISK STRATIFICATION OF GISTs
The aggressiveness of GISTs depends on the size and mitotic index of GISTs, and also
anatomic site of involvement and patient’s age. As per the National Institute Health
(NIH) GIST consensus criteria, GISTs are categorized into very low risk, low risk,
intermediate risk and high risk groups as shown in Table 1[47].
As per NIH classification, 44% of GISTs belong to high-risk category, 24%
intermediate risk and 32% low risk/very low risk category. The significance of mitotic
index also depends on location of the GISTs. Small bowel, esophageal and rectal GISTs
are more aggressive and are associated with worse prognosis and more recurrence
than gastric GISTs of the same size, mitotic index and tumor rupture[48]. Size ≥ 10 cm,
mitotic rate ≥ 5 per 50 HPF and location of the GIST (non-gastric) and tumor rupture
can independently predict recurrence of the GIST after complete surgical resection[49].
A modified version of NIH risk assessment has been proposed by Joensuu as shown in
Table 2. Currently, the Joensuu classification is widely used. Tumor size, mitotic index,
primary tumor site and tumor rupture are included in this version. Patients belonging
to high-risk category have 15%-20% risk of having recurrent disease[50]. Besides the
above factors, certain mutations at the genetic level can be associated with poor
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Table 1 National Institute Health gastrointestinal stromal tumor consensus criteria
Risk category

Tumor size (cm)

Mitotic count per 50 HPF

Very low risk

<2

<5

Low risk

2-5

<5

Intermediate risk

<5

6–10

5-10

<5

>5

>5

> 10

Any mitotic rate

Any size

> 10

High risk

HPF: High power field.

Table 2 Joensuu criteria for gastrointestinal stromal tumor risk assessment
Risk category

Tumor size (cm)

Mitotic index (per 50 HPF)

Primary tumor site

Very low

<2

≤5

Any

Low

2.1-5

≤5

Any

Intermediate

2.1–5

>5

Gastric

<5

6–10

Any

5.1-10

≤5

Gastric

Any

Any

Tumor rupture

> 10

Any

Any

Any

> 10

Any

>5

>5

Any

2.1–5

>5

Non-gastric

5.1-10

≤5

Non-gastric

High

HPF: High power field.

outcome. These include KIT exon 9 mutations and deletions affecting codons 557-558
(exon 11 deletions) of the c-KIT gene[51]. KIT exon 9 mutations are almost exclusively
found in the small bowel. As mentioned before PDGFRA mutation due to Asp842Val
substitution in exon18 leads to resistance to tyrosine kinase inhibitor imatinib
mesylate. PDGFRA mutations are usually seen in gastric GISTs. A simplified way of
stratifying the risk of GISTs is to use “rule of fives” for low risk and high risk
groups[52]. Both high risk and intermediate risk gastric GISTs are > 5 cm in size and
have > 5 mitosis per 50 HPF whereas non-gastric GISTs belong to high risk category if
they are either > 5 cm in size or have > 5 mitosis per 50 HPF. Gastric GISTs < 10 cm
and < 5 mitosis per HPF can metastasize in about 2 to 3% of cases whereas gastric
GISTs > 10 cm and > 5 mitosis per 50 HPF can metastasize in about 86% of cases. 11%
of gastric GISTs > 10 cm with < 5 mitosis per HPF and 15% of gastric GISTs < 5 cm
with > 5 mitosis per 50 HPF can metastasize. Gastric antral GISTs carry a better
prognosis than gastric fundic or gastroesophageal junction GISTs[53]. Small intestinal
GISTs > 10 cm with mitosis ≤ 5 per 50 HPF or ≤ 5 cm with mitosis > 5 per 50 HPF have
metastatic potential of > 50% whereas small intestinal GISTs > 5 to 10 cm with mitosis
< 5 per 50 HPF have metastatic potential of 24%[54].
The latest staging system of GIST is the 2018 American Joint Committee of Cancer
tumor node metastasis system as shown in Table 3 and Table 4[55].
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Table 3 American Joint Committee on Cancer tumor node metastasis system for gastric and omental gastrointestinal stromal tumor
Stage TNM

Mitotic rate

Stage description

IA

T1 or T2; N0; M0

Low (G1): mitotic rate 5/50 per
HPF or less

T1: Tumor ≤ 2 cm; T2: Tumor > 2 cm but ≤ 5 cm; N0: no regional lymph node
metastasis; M0: No distant metastasis

IB

T3; N0; M0

Low (G1)

T3: Tumor > 5 cm but ≤ 10 cm; N0: no regional lymph node metastasis; M0: No
distant metastasis

II

T1; N0; M0 or T2; N0;
M0 or T4; N0; M0

High (G2): mitotic rate > 5/50
HPF; High (G2); or Low (G1)

T1: Tumor ≤ 2 cm; T2: Tumor > 2 cm but ≤ 5 cm; T4: Tumor > 10 cm in greatest
dimension; N0: no regional lymph node metastasis; M0: No distant metastasis

IIIA

T3; N0; M0

High (G2)

T3: Tumor > 5 cm but ≤ 10 cm; N0: no regional lymph node metastasis; M0: No
distant metastasis

IIIB

T4; N0; M0

High (G2)

T4: Tumor > 10 cm in greatest dimension; N0: no regional lymph node metastasis;
M0: No distant metastasis

IV

Any T; N1; M0 or Any Any rate or Any rate
T; Any N; M1

N1: Regional lymph node metastasis; M1: Distant metastasis

TNM: Tumor node metastasis; HPF: High power field.

Table 4 American Joint Committee on Cancer tumor node metastasis system for small intestine, esophagus, colon, rectum, or
peritoneum
Stage TNM

Mitotic rate

Stage description

I

T1 or T2; N0; M0

Low (G1): mitotic rate 5/50
per HPF or less

T1: Tumor ≤ 2 cm; T2: Tumor > 2 cm but ≤ 5 cm; N0: no regional lymph node metastasis;
M0: No distant metastasis

II

T3; N0; M0

Low (G1)

T3: Tumor > 5 cm but ≤ 10 cm; N0: no regional lymph node metastasis; M0: No distant
metastasis

IIIA

T1; N0; M0 or T4; N0;
M0

High (G2): mitotic rate >
5/50 HPF; or Low (G1)

T1: Tumor ≤ 2 cm; T4: Tumor > 10 cm in greatest dimension; N0: no regional lymph node
metastasis; M0: No distant metastasis

IIIB

T2; N0; M0 or T3; N0;
M0 or T4; N0; M0

High (G2); or High (G2); or
High (G2)

T2: Tumor > 2 cm but ≤ 5 cm; T3: Tumor > 5 cm but ≤ 10 cm; T4: Tumor > 10 cm in greatest
dimension; N0: no regional lymph node metastasis; M0: No distant metastasis

IV

Any T; N1; M0 or Any Any rate or Any rate
T; Any N; M1

N1: Regional lymph node metastasis; M1: Distant metastasis

TNM: Tumor node metastasis; HPF: High power field.

TREATMENT
The treatment of GISTs depends on risk stratification. The different therapeutic
modalities of GISTs include surgery, endoscopic resection, medical therapy,
radiotherapy, chemotherapy, hepatic artery embolization, chemoembolization and
radiofrequency ablation.

SURGERY
Surgery is the treatment of choice for localized symptomatic GISTs, ≥ 2 cm GISTs and
GISTs with suspicious EUS features of malignancy as mentioned before[56]. According
to National Comprehensive Cancer Network (NCCN), asymptomatic patients with
GISTs < 2 cm with benign EUS features can be followed conservatively with annual
EUS and/or esophagogastroduodenoscopy[57]. But surgery should be considered if the
GIST increases in size during follow-up. R0 resection (negative margin) of the GIST is
the main aim of surgery. As GISTs almost never metastasize to the lymph nodes,
routine local lymph node dissection is not necessary unless suspected on imaging or
endosonography. The surgical approach depends on the location of the GIST, its
adherence or invasion into adjacent structures and the patient’s general medical status.
Laparoscopic surgery (wedge resection) is indicated if the GIST is less than 5 cm in
size[58]. As GISTs are usually surrounded by a pseudocapsule, enucleation technique is
tried for small posterior wall GIST of the stomach at the gastroesophageal junction or
small esophageal GIST to preserve the organ’s function. Esophagectomy is done for
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large esophageal GIST. Depending on the size, number and location of gastric GISTs,
surgical options include wedge partial resection of the stomach, Biliroth I partial
gastrectomy or gastroduodenostomy, Biliroth II partial gastrectomy or
gastrojejunostomy and total gastrectomy with Roux-en-Y reconstruction. If the
duodenal GIST is small and far enough away from the ampulla of Vater, segmental
duodenal resection with end to end anastomosis can be done. But if the GIST is close to
the ampulla of Vater or adherent to adjacent organs, pancreaduodenectomy or
Whipple resection is required. In case of jejunal, ileal or colonic GISTs, segmental
resection with anastomosis of the divided ends are done. Surgery for rectal GISTs
depends on the location: if the GIST is in the upper rectum or not too close to the anal
sphincter, rectal resection with anastomosis of the divided colonic end to the
remaining rectum can be done with or without temporary colostomy. If the GIST is
close to the anal sphincter, abdominoperineal resection of the rectum (resection of
rectum and anus with permanent sigmoid colostomy) is done[59]. Novel techniques to
remove rectal GISTs have been described. These include transanal endoscopic
operation[60] and transanal minimal invasive surgery[61]. Appendiceal GISTs are
extremely rare and treated by simple laparoscopic appendectomy.
Total 80% of the GISTs are single and surgery is considered as the first line therapy.
But if the GIST is large in size and surgical resection can be difficult, shrinkage of the
GIST can be done by giving TKI therapy (neoadjuvant therapy) prior to surgery.
Sometimes, debulking surgery is also considered in case of potentially resectable
metastatic GISTs. Surgery is also required emergently in case of bleeding gastric or
duodenal GISTs.

ENDOSCOPIC RESECTION
Endoscopic treatment is mainly used for the treatment of GISTs of the upper GI tract
for patients with no recurrence or metastasis[62]. The available endoscopic resection
methods include endoscopic enucleation, endoscopic band ligation (EBL), endoscopic
submucosal dissection (ESD), endoscopic submucosal excavation (ESE), submucosal
tunneling endoscopic resection (STER), endoscopic full-thickness resection (EFTR),
and laparoscopic and endoscopic cooperative surgery (LECS)[63-71]. Endosonographically, gastric GIST can be classified into 4 types according to their location
in the mucularis propria (MP). Type I GIST protrudes into the lumen like a polyp and
is attached to the MP by a narrow connection. Type II GIST also protrudes into the
lumen but is attached to the MP by a wider connection. Type III GIST is centrally
located in the gastric wall. Type IV protrudes outwards towards the serosa of the
gastric wall[46]. Endoscopic enucleation can be done for type I and possibly for type II
GISTs. Type III and type IV GISTs can be treated by other endoscopic methods which
include EBL, ESD, ESE, STER, EFTR and LECs. Small (≤ 4 cm) gastric GISTs can be
resected safely by endoscopic methods although intermediate or high risk GISTs may
require adjuvant TKI therapy and/or additional surgery to reduce the chance of
metastasis and recurrence[72].

MEDICAL THERAPY
Medical therapy includes TKIs which has revolutionized the treatment of metastatic
and unresectable GISTs. TKI is given in patients with metastatic and unresectable
GISTs as a definitive therapy. Metastatic lesion should be biopsied to confirm the
diagnosis and mutational analysis should be assessed. Adjuvant therapy is given after
surgery and continued for 3 years to decrease the chance of recurrence of GISTs with
high (> 50%) risk of recurrence[73]. A prognostic nomogram was developed at the
Memorial Sloan-Kettering Cancer Center for recurrence-free survival (RFS) after
complete surgical resection of localized GISTs using tumor size (in cm), location
(stomach, small intestine, colon/rectum, or other), and mitotic index (< 5 or ≥ 5
mitoses per 50 high power fields). The nomogram is able to predict RFS for patients
with completely resected GIST and can be used to select patients for adjuvant
therapy[74]. Neoadjuvant therapy is given preoperatively for 6 to 12 mo (although the
optimal duration is not known) in patients with large GISTs to decrease the size of the
tumor to enable resectability. Neoadjuvant therapy should also be considered for
organ and function-preserving surgeries like esophagectomy for esophageal GIST,
pancreatoduodenectomy for duodenal GIST and abdominoperineal resection for rectal
GIST[75]. PET/CT should be done one month after beginning neoadjuvant therapy to
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evaluate response to the treatment. TKI is also recommended in case of tumor rupture
during surgery and should be continued for at least 3 years to lifelong. Some authors
also recommend neoadjuvant therapy when GISTs present emergently with acute
upper GI bleeding[76]. There is no guideline on the post-operative management of
patients who received neoadjuvant therapy. Patients with high-risk GISTs, TKI should
be continued for several years. Imatinib is the first-line therapy Sunitinib, the secondline and Regorafenib, the third-line TKI used as adjuvant and neoadjuvant therapy[77].
The effectiveness of TKI depends on KIT and PDGFRA mutation. 90% of GISTs
containing KIT exon 11 mutation and 50% of GISTs containing KIT exon 9 mutation
respond to imatinib. Dose escalation of TKI may be needed to improve response.
GISTs containing KIT exon 13 and 14 mutation are sensitive to sunitinib. Regorafenib
improves progression free survival for locally advanced and unresectable GISTs which
do not respond to imatinib or sunitinib[78]. Recently, a new TKI known as Avapritinib
has been added for unresectable/metastatic GISTs with PDGFRA exon 18 mutation,
including PDGFRA D842V[79]. Avapritinib is also indicated in patients with GISTS
which keep growing despite imatinib or other TKI therapy. So testing for KIT and
PDGFRA gene mutation is suggested, particularly when medical therapy is going to be
administered. Multi-disciplinary team with experience and expertise in GISTs should
be involved prior to initiation of therapy. According to NCCN guideline, resectable
GISTs with minimum morbidity should be resected and risk assessment should be
evaluated on the pathology of the GISTs as shown in Table 5. Patients with significant
risks of recurrence (intermediate or high risk depending on size, mitotic rate and
location) should be given TKI therapy. Resectable GISTs with significant morbidity
should be considered for preoperative TKI therapy to decrease surgical morbidity.
Imaging should be done to evaluate treatment response. If the patient responds to TKI
therapy, TKI should be continued and surgery should be done. If the GIST progresses
on TKI therapy, surgery should be done if feasible, but if surgery is not feasible: (1) For
limited progression – (a) continue TKI (imatinib or avapritinib) and consider other
options like resection, if feasible or radiofrequency ablation (RFA), embolization,
chemoembolization and palliative radiation therapy for bone metastasis; and (b)
increase the dose of imatinib as tolerated or change to sunitinib. Imaging should be
done to evaluate therapeutic response and patient adherence; and (2) For widespread
progression – (a) increase the dose of imatinib as tolerated or change imatinib to
sunitinib; (b) If GISTs progresses on sunitinib, then change to regorafenib; and (c) If
GISTs progresses on regorafinib, change to avapritinib.
Imaging should be done to evaluate therapeutic response and patient adherence.
If GISTs keep progressing despite giving imatinib, sunitinib, regorafinib and
avapritinib, other options include enrolling the patients into clinical trials, use systemic
therapy and agents against GIST (sorafenib, nilotinib, pazopanib, everolimus plus TKI
and dasatinib for patients with D842V mutation) based on limited data or to give best
supportive care.
Small gastric GIST (< 2 cm) should be evaluated by EUS-guided FNA and imaging.
If the GIST has high-risk features, complete resection should be done. But if there is no
high-risk feature, periodic endoscopic and imaging surveillance should be done.
Micro-GISTs (< 1 cm) are generally benign irrespective of their mitotic rate.

TREATMENT OF UNRESECTABLE, METASTATIC OR RECURRENT GISTs
Baseline imaging and percutaneous image guided biopsy should be appropriate to
establish metastatic disease. Patient should be started on imatinib or avapritinib.
Follow-up imaging should be done to evaluate for treatment response. Wang et al[80]
did a single center analysis in which patients with advanced and metastatic/recurrent
GISTs were given imatinib mesylate for a median period of 8.2 mo preoperatively and
tumor shrinkage was observed in almost 30% of cases. If the response is good and the
disease remains stable, continue imatinib or avapritinib, and surgery consult should be
done to consider resection. If resection is not possible, continue imatinib or avapritinib.
If the disease is progressive, dose escalation and change of TKI should be considered.
If GISTs keep progressing despite giving imatinib, sunitinib, regorafinib and
avapritinib, other options include to enroll the patients into clinical trials, use systemic
therapy and agents against GIST (sorafenib, nilotinib, pazopanib, everolimus plus TKI
and dasatinib for patients with D842V mutation) based on limited data or to give best
supportive care.
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Table 5 Treatment options of resectable gastrointestinal stromal tumors
Resectable GISTs with minimum morbidity

Resectable GISTs with significant morbidity

Resection followed by risk stratification on
pathology: (1) Very low or low risk category – no
TKI; and (2) Intermediate or high risk category TKI.

Preoperative TKI: (1) If patient responds to TKI: continue TKI and proceed with surgery; and (2) If patient does not respond to TKI: surgery if feasible. If surgery not feasible: (a) For
limited progression -options include radiofrequency ablation, embolization, chemoembolization, and palliative radiation; and (b) For widespread progression – increase the dose of
imatinib as tolerated, If that fails – sunitinib followed by regorafinib followed by avapritinib should be tried. If GIST continues to progress despite TKIs, other options include clinical
trials, systemic agents against GIST and best supportive care.

GIST: Gastrointestinal stromal tumor; TKI: Tyrosine kinase inhibitor.

FOLLOW UP AND SURVIVAL
There is no current guideline for follow up of patients who have undergone GIST
resection to evaluate for recurrence or metastasis. Current practice is based on
clinician’s opinion taking into account the tumor site, size and mitotic index[81]. The
imaging modality and follow up interval varies from institution to institution. Very
low risk category patients may not need routine follow up although the risk of
recurrence is not zero. Low risk category patients can be followed up by doing CT scan
every 6 mo for 5 years. Intermediate to high risk category patients should be more
closely followed-up with CT scan every 3 to 4 mo for 3 years, then every 6 months for
5 years, and then yearly[82]. PET/CT is more sensitive than CT in detecting response,
resistance and recurrence following TKI therapy when it is used for neoadjuvant,
adjuvant or definitive therapy[83].
The survival of patients with GIST depends on several factors which include risk
category or stage of the GIST, the type of treatment patient received and recurrence of
GIST after treatment. If the GIST is localized, the 5-year survival rate is 94%. It
becomes 82% if there is local spread of the GIST. If the GIST has distant metastasis at
the time of diagnosis, the 5-year survival rate becomes 52%[84].

SUMMARY
GISTs are well-circumscribed mesenchymal tumors (median size 2.7 cm to 8.9 cm)
originating from the muscular layer of the gastrointestinal tract mostly seen in the
stomach and small bowel but they can be found in any part of the gastrointestinal
tract. The incidence of GISTs has increased over the last few decades possibly due to
increased detection due to increased availability of imaging studies, endoscopic and
endosonographic procedures. C-KIT gene mutation with constitutive activation of
tyrosine kinase and ICC hyperplasia is the pathogenic mechanism seen in most GISTs.
Mutation in PDGFRA gene can also lead to the formation of GISTs. The importance of
PDGFRA mutation (due to Asp842Val substitution in exon18) is that they are resistant
to imatinib therapy. KIT and PDGFRA mutations are not detectable in 15% of GISTs
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when they are called wild-type GISTs. Immunohistochemistry is important to
differentiate GISTs from other mesenchymal tumors like leiomyoma. GISTs stain
positive for KIT, CD34, CD117 and DOG1. Histologic features of GISTs include spindle
cell type, epitheloid type or mixed type. GISTs remain silent when they are small in
size but when they increase in size, they can produce various manifestations which
include gastrointestinal bleeding, abdominal pain, small bowel obstruction, dysphagia
and proctalgia depending on their location. CT, MRI, PET/CT, endoscopic procedures
and EUS are done in the diagnostic and metastatic evaluation as well as in following
response to treatment. Tissue acquisition is done by EUS FNA/TCB, or postoperatively or sometimes by percutaneous biopsy in case of metastatic GISTs. Surgery
is the treatment of choice for any potentially resectable GIST greater than 2 cm in size
or if the GIST is localized and symptomatic or if the GIST has suspicious malignant
features on EUS. Type of surgery depends on the location of GISTs. Now there is an
increased interest in endoscopic resection of gastric GISTs < 4 cm in size, and various
endoscopic resection methods are available. TKI has multiple roles in the treatment of
GISTs: (1) As a neoadjuvant therapy preoperatively for 6 to 12 mo for tumor
cytoreduction of a large GIST to make it operable; (2) As an adjuvant therapy postoperatively to prevent recurrence of GISTs for a minimum of 3 years; and (3) As a
neoadjuvant therapy (to be considered) for organ and function-preserving surgeries
like esophagectomy, pancreatoduodenectomy and abdominoperineal resection for
esophageal, duodenal and rectal GISTs.

CONCLUSION
GIST is an important gastrointestinal tumor. Although they can be asymptomatic
when small, they can have a variety of clinical presentations when they are large or
rapidly growing. They are diagnosed by imaging, endoscopic and endosonographic
studies or sometimes post-operatively. They have distinct genetic mutations,
immunohistochemical features and risk stratification criteria. Surgical or endoscopic
resection and TKI are the main modalities of treatment. Clinical trials are ongoing for
refractory cases. Future treatment options will change as we discover more and more
drugs against GISTs.
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